Mylan EPS - Earnings per Share 2006-2018 | MYL

Mylan annual and quarterly earnings per share history from 2006 to 2018. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Mylan EPS for the quarter ending September 30, 2018 was $0.34, a 112.5% increase year-over-year.
  • Mylan EPS for the twelve months ending September 30, 2018 was $1.05, a 35.19% decline year-over-year.
  • Mylan 2017 annual EPS was $1.3, a 41.3% increase from 2016.
  • Mylan 2016 annual EPS was $0.92, a 45.88% decline from 2015.
  • Mylan 2015 annual EPS was $1.7, a 27.35% decline from 2014.
Mylan Annual EPS
2017 $1.30
2016 $0.92
2015 $1.70
2014 $2.34
2013 $1.58
2012 $1.52
2011 $1.22
2010 $0.68
2009 $0.30
2008 $-1.10
2007 $-4.53
2007 $0.99
2006 $0.79
2005 $0.74
Mylan Quarterly EPS
Q3 2018 $0.34
Q2 2018 $0.07
Q1 2018 $0.17
Q4 2017 $0.47
Q3 2017 $0.16
Q2 2017 $0.55
Q1 2017 $0.12
Q4 2016 $0.79
Q3 2016 $-0.23
Q2 2016 $0.33
Q1 2016 $0.03
Q4 2015 $0.42
Q3 2015 $0.83
Q2 2015 $0.32
Q1 2015 $0.13
Q4 2014 $0.47
Q3 2014 $1.26
Q2 2014 $0.32
Q1 2014 $0.29
Q4 2013 $0.45
Q3 2013 $0.40
Q2 2013 $0.46
Q1 2013 $0.27
Q4 2012 $0.38
Q3 2012 $0.51
Q2 2012 $0.33
Q1 2012 $0.30
Q4 2011 $0.30
Q3 2011 $0.36
Q2 2011 $0.33
Q1 2011 $0.23
Q4 2010 $-0.01
Q3 2010 $0.33
Q2 2010 $0.16
Q1 2010 $0.20
Q4 2009 $0.01
Q3 2009 $-0.13
Q2 2009 $0.19
Q1 2009 $0.23
Q4 2008 $-0.05
Q3 2008 $0.47
Q2 2008 $-0.05
Q1 2008 $-1.47
Q4 2007 $-5.14
Q3 2007 $0.60
Q2 2007 $0.32
Q1 2007 $-0.31
Q4 2006 $0.63
Q3 2006 $0.36
Q2 2006 $0.35
Q1 2006 $0.00
Q4 2005 $0.22
Q3 2005 $0.16
Q2 2005 $0.16
Q1 2005 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $15.680B $11.908B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $51.359B 8.82
Teva Pharmaceutical Industries (TEVA) Israel $19.310B 5.92
Bausch Health Cos (BHC) Canada $8.440B 6.11
Dr Reddy's Laboratories (RDY) India $5.963B 23.78
Supernus Pharmaceuticals (SUPN) United States $1.944B 18.42
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.737B 2.90
Amphastar Pharmaceuticals (AMPH) United States $0.973B 105.55
Homology Medicines (FIXX) United States $0.918B 0.00
Assembly Biosciences (ASMB) United States $0.616B 0.00
Akorn (AKRX) United States $0.543B 0.00
CymaBay Therapeutics (CBAY) United States $0.521B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.421B 0.00
Voyager Therapeutics (VYGR) United States $0.364B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.265B 0.00
Sol-Gel Technologies (SLGL) Israel $0.115B 0.00
Teligent (TLGT) United States $0.097B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.083B 0.00
Aevi Genomic Medicine (GNMX) United States $0.077B 0.00
Acasti Pharma (ACST) Canada $0.056B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.055B 0.00
Evoke Pharma (EVOK) United States $0.046B 0.00
Agile Therapeutics (AGRX) United States $0.029B 0.00
China Pharma Holdings (CPHI) China $0.011B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.005B 0.00